

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \ \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in Caplus
NEWS	6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	16	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	17	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	18	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	19	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	20	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS EXPRESS		JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:31:47 ON 09 SEP 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 17:33:04 ON 09 SEP 2004

FILE 'USPATFULL' ENTERED AT 17:33:04 ON 09 SEP 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 17:33:04 ON 09 SEP 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 17:33:04 ON 09 SEP 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:33:04 ON 09 SEP 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 17:33:04 ON 09 SEP 2004  
COPYRIGHT (C) 2004 International Food Information Service

=> s hyperglycemia or hypoglycemia  
L1 47616 HYPERGLYCEMIA OR HYPOGLYCEMIA

=> s l1 and non-peptidyl compound  
L2 17 L1 AND NON-PEPTIDYL COMPOUND

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 17 USPATFULL on STN  
TI Method of regulating glucose metabolism, and reagents related thereto  
AB The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.

ACCESSION NUMBER: 2004:227921 USPATFULL  
TITLE: Method of regulating glucose metabolism, and reagents related thereto  
INVENTOR(S): Bachovchin, William W., Melrose, MA, UNITED STATES  
Plaut, Andrew G., Lexington, MA, UNITED STATES  
Drucker, Daniel, Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004176307	A1	20040909
APPLICATION INFO.:	US 2004-794316	A1	20040304 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-190267, filed on 3 Jul 2002, PENDING Continuation of Ser. No. US 2000-628225, filed on 28 Jul 2000, PENDING Continuation of Ser. No. WO 1999-US2294, filed on 2 Feb 1999, PENDING		

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 1998-73409P 19980202 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA,  
02110-2624  
NUMBER OF CLAIMS: 37  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Page(s)  
LINE COUNT: 2431

L2 ANSWER 2 OF 17 USPATFULL on STN

TI Insulin-like growth factor agonist molecules

AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:85155 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6716586	B1	20040406
APPLICATION INFO.:	US 2000-724065		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5371		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 17 USPATFULL on STN

TI Insulin-like growth factor agonist molecules

AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:78964 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6713451	B1	20040330
APPLICATION INFO.:	US 2000-724062		20001128 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865  
Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Romeo, David S.  
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP

NUMBER OF CLAIMS: 8  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)  
LINE COUNT: 5379  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 17 USPATFULL on STN

TI DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof  
AB This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:72563 USPATFULL  
TITLE: DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof  
INVENTOR(S): Gerald, Christophe P. G., Ridgewood, NJ, United States  
Jones, Kenneth A., Bergenfield, NJ, United States  
Bonini, James A., Oakland, NJ, United States  
Borowsky, Beth E., Montclair, NJ, United States  
Craig, Douglas A., Emerson, NJ, United States  
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6709831	B1	20040323
APPLICATION INFO.:	US 1999-405558		19990924 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-255368, filed on 22 Feb 1999, now patented, Pat. No. US 6262246 Continuation-in-part of Ser. No. US 1998-161113, filed on 25 Sep 1998, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Eyler, Yvonne		
ASSISTANT EXAMINER:	Murphy, Joseph F.		
LEGAL REPRESENTATIVE:	White, John P., Cooper & Dunham LLP		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	39 Drawing Figure(s); 33 Drawing Page(s)		
LINE COUNT:	5391		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L2 ANSWER 5 OF 17 USPATFULL on STN

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:41453 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693079	B1	20040217
APPLICATION INFO.:	US 2000-724157		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5389		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 17 USPATFULL on STN

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:41452 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693078	B1	20040217
APPLICATION INFO.:	US 2000-724095		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 65 Drawing Figure(s); 44 Drawing Page(s)  
LINE COUNT: 5369  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 17 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:34008 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6689751	B1	20040210
APPLICATION INFO.:	US 2000-723912		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5377		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 17 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:21596 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Devonport, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6683053	B1	20040127
APPLICATION INFO.:	US 2000-723913		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		

LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Dreger, Esq., Ginger R., Heller  
Ehrman White & McAuliffe LLP  
NUMBER OF CLAIMS: 7  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)  
LINE COUNT: 5367  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 17 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any  
one of its binding proteins and not to a human IGF receptor. These IGF  
agonist compounds, which include peptides, are useful to increase serum  
and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:15030 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6680298	B1	20040120
APPLICATION INFO.:	US 2000-724114		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	44 Drawing Figure(s); 49 Drawing Page(s)		
LINE COUNT:	5376		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 17 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any  
one of its binding proteins and not to a human IGF receptor. These IGF  
agonist compounds, which include peptides, are useful to increase serum  
and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:9592 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6677305	B1	20040113
APPLICATION INFO.:	US 2000-723873		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852,		

filed on 4 Apr 1997, now patented, Pat. No. US 6121416  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Romeo, David S.  
LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe,  
LLP  
NUMBER OF CLAIMS: 4  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)  
LINE COUNT: 5359  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 17 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any  
one of its binding proteins and not to a human IGF receptor. These IGF  
agonist compounds, which include peptides, are useful to increase serum  
and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:296863 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6645775	B1	20031111
APPLICATION INFO.:	US 2000-723931		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	67 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5386		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 17 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any  
one of its binding proteins and not to a human IGF receptor. These IGF  
agonist compounds, which includes peptides, are useful to increase serum  
and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:279179 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

NUMBER	KIND	DATE
--------	------	------



-----

PATENT INFORMATION: US 6635619 B1 20031021  
 APPLICATION INFO.: US 2000-724127 20001128 (9)  
 RELATED APPLN. INFO.: Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865  
 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Romeo, David S.  
 LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller, Ehrman, White & McAuliffe, LLP

NUMBER OF CLAIMS: 5  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 44 Drawing Figure(s); 49 Drawing Page(s)  
 LINE COUNT: 5375

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 17 USPATFULL on STN  
 TI Insulin-like growth factor agonist molecules  
 AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2003:273418 USPATFULL  
 TITLE: Insulin-like growth factor agonist molecules  
 INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
 Lowman, Henry B., El Granada, CA, United States  
 Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
 PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
-----			
PATENT INFORMATION:	US 6632794	B1	20031014
APPLICATION INFO.:	US 2000-723547		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5360		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 17 USPATFULL on STN  
 TI Insulin-like growth factor agonist molecules  
 AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2003:246897 USPATFULL  
 TITLE: Insulin-like growth factor agonist molecules  
 INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND

PATENT ASSIGNEE(S): Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C.A.F., St. Albans, UNITED KINGDOM  
Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6620789	B1	20030916
APPLICATION INFO.:	US 2000-723901		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5398		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L2 ANSWER 15 OF 17 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2003:222090 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6608031	B1	20030819
APPLICATION INFO.:	US 2000-723890		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	68 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5363		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L2 ANSWER 16 OF 17 USPATFULL on STN  
TI Method of regulating glucose metabolism, and reagents related thereto  
AB The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and

LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:220218 USPATFULL  
TITLE: Method of regulating glucose metabolism, and reagents related thereto  
INVENTOR(S): Bachovchin, William W., Melrose, MA, UNITED STATES  
Plaut, Andrew G., Lexington, MA, UNITED STATES  
Drucker, Daniel, Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153509	A1	20030814
APPLICATION INFO.:	US 2002-190267	A1	20020703 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-628225, filed on 28 Jul 2000, PENDING Continuation of Ser. No. WO 1999-US2294, filed on 2 Feb 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-73409P	19980202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Matthew P. Vincent, Patent Group, Foley, Hoag & Eliot LLP, One Post Office Square, Boston, MA, 02109	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2430	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 17 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:97888 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, New Zealand  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, United Kingdom  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251865	B1	20010626
APPLICATION INFO.:	US 1998-52888		19980331 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David		
LEGAL REPRESENTATIVE:	Hasak, Janet E.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	4925		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:31:47 ON 09 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 17:33:04  
ON 09 SEP 2004

L1 47616 S HYPERGYLCEMIA OR HYPOGLYCEMIA  
L2 17 S L1 AND NON-PEPTIDYL COMPOUND

=> s l1 and treatment

L3 13598 L1 AND TREATMENT

=> s l3 and insulin agonist

L4 10 L3 AND INSULIN AGONIST

=> s insulin antagonist

L5 135 INSULIN ANTAGONIST

=> s l5 and l4

L6 1 L5 AND L4

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 1 USPATFULL on STN

TI Insulin-associated peptides with effects on cerebral health

AB The present invention provides compositions and methods for ameliorating neurological, attention, or memory disorders and improving learning and cognition through the delivery of insulin A-chain and analogs thereof to a subject. Insulin A-chain, peptides comprising the 21 amino acid sequence GIVEQ CCASV CSLYQ LENYC N (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of insulin A-chain peptide or a functional analogs thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:19356 USPATFULL

TITLE: Insulin-associated peptides with effects on cerebral health

INVENTOR(S): During, Matthew J., Philadelphia, PA, UNITED STATES  
Haile, Colin N., Katy, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014660	A1	20040122
APPLICATION INFO.:	US 2003-430545	A1	20030506 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-378318P	20020506 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	2477	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:31:47 ON 09 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 17:33:04  
ON 09 SEP 2004

L1 47616 S HYPERGLYCEMIA OR HYPOGLYCEMIA  
L2 17 S L1 AND NON-PEPTIDYL COMPOUND  
L3 13598 S L1 AND TREATMENT  
L4 10 S L3 AND INSULIN AGONIST  
L5 135 S INSULIN ANTAGONIST  
L6 1 S L5 AND L4

=> s l5 and l1

L7 32 L5 AND L1

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 10 USPATFULL on STN

TI Methods of reducing hypoglycemic episodes in the **treatment** of  
diabetes mellitus

AB The present invention provides compositions and methods for reducing  
hypoglycemic episodes experienced by a subject in need of  
**treatment** for diabetes mellitus, said method comprising orally  
administering an amount of an insulin polypeptide-oligomer conjugate to  
the subject, wherein: i) the amount of the insulin polypeptide-oligomer  
conjugate reduces the number and/or severity of hypoglycemic episodes  
experienced by the subject during a given time period when compared with  
the number and/or severity of hypoglycemic episodes that would have been  
experienced during a similar time period by the subject or by subjects  
in a control group parenterally administered insulin or an insulin  
analog in an amount that provides a substantially equivalent level of  
glycemic control; and ii) the oligomer of the insulin  
polypeptide-oligomer conjugate comprises a hydrophilic moiety and a  
lipophilic moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:51436 USPATFULL

TITLE: Methods of reducing hypoglycemic episodes in the  
**treatment** of diabetes mellitus

INVENTOR(S): Still, James Gordon, Raleigh, NC, UNITED STATES  
Kosutic, Gordana, Raleigh, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038867	A1	20040226
APPLICATION INFO.:	US 2003-461199	A1	20030613 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-388988P	20020613 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2168	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 10 USPATFULL on STN

TI Insulin-associated peptides with effects on cerebral health

AB The present invention provides compositions and methods for ameliorating neurological, attention, or memory disorders and improving learning and cognition through the delivery of insulin A-chain and analogs thereof to a subject. Insulin A-chain, peptides comprising the 21 amino acid sequence GIVEQ CCASV CSLYQ LENYC N (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of insulin A-chain peptide or a functional analogs thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:19356 USPATFULL  
TITLE: Insulin-associated peptides with effects on cerebral health  
INVENTOR(S): During, Matthew J., Philadelphia, PA, UNITED STATES  
Haile, Colin N., Katy, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014660	A1	20040122
APPLICATION INFO.:	US 2003-430545	A1	20030506 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-378318P	20020506 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	2477	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 10 USPATFULL on STN  
TI Single-chain insulin analog and a polynucleotide sequence encoding the analog  
AB The subject matter of the invention is directed to a single-chain insulin analog that is used to treat diabetes by gene therapy methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:268156 USPATFULL  
TITLE: Single-chain insulin analog and a polynucleotide sequence encoding the analog  
INVENTOR(S): Lee, Hyun Chul, Seodaemungu Hongeundong 268,  
Dongdo-academyhouse A-402, Seoul, KOREA, REPUBLIC OF  
Kim, Su-Jin, Dukyanggu Haengsindong 938 Haibit  
1819-1304, Goyangsi, KOREA, REPUBLIC OF  
Kim, Kyung Sup, Yongdeungpogu Yeoyeedodong Samik, Apt.  
B-202, Seoul, KOREA, REPUBLIC OF  
Shin, Hang-Cheol, Seochogu Wonjidong 401-37, Seoul,  
KOREA, REPUBLIC OF  
Yoon, Ji-Won, 206 Edgeview Drive, N.W., Calgary,  
Alberta, CANADA T3A 4X5

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6630348	B1	20031007
APPLICATION INFO.:	US 2000-706690		20001107 (9)

NUMBER	DATE
--------	------

-----  
PRIORITY INFORMATION: KR 2000-58003 20001002  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Kemmerer, Elizabeth  
ASSISTANT EXAMINER: Bunner, Bridget E.  
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 7 Drawing Page(s)  
LINE COUNT: 1243  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPATFULL on STN  
TI Methods of treating diabetes mellitus  
AB Methods of treating diabetes mellitus in a patient in need of such  
**treatment** include administering an effective amount of an  
insulin drug to the patient in order to treat diabetes mellitus in the  
patient. Methods according to the present invention may "activate" the  
liver, potentially restoring normal glucose homeostasis to individuals  
suffering from diabetes mellitus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:71941 USPATFULL  
TITLE: Methods of treating diabetes mellitus  
INVENTOR(S): Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES  
Price, Christopher H., Chapel Hill, NC, UNITED STATES  
Still, James Gordon, Raleigh, NC, UNITED STATES  
Filbey, Jennifer Ann, Raleigh, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003050228	A1	20030313
APPLICATION INFO.:	US 2002-75097	A1	20020213 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-269198P	20010215 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627	
NUMBER OF CLAIMS:	230	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	3140	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPATFULL on STN  
TI **Treatment** of acute and chronic liver disease  
AB The present invention relates to IGF-1 **treatment** of an  
individual, such as e.g. a human being, suffering from an acute or  
chronic liver disease including hepatic cirrhosis. Acute and chronic  
liver disease according to the invention are characterized by low  
circulating IGF-1 and IGFBP3 levels. According to one preferred  
embodiment of the present invention, IGF-1 is administered to a human  
being subcutaneously, preferably in the thigh or the abdominal skin, and  
preferably in two daily doses of about 50 microgram/kg twice a day. The  
present invention demonstrates that this dosis regime is able to restore  
normal IGF-1 levels in patients with liver cirrhosis, and the dose is  
well-tolerated by the patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:48572 USPATFULL

TITLE: Treatment of acute and chronic liver disease  
INVENTOR(S): Grofte, Thorbjorn, Viby J., DENMARK  
Vilstrup, Hendrik, Risskov, DENMARK  
PATENT ASSIGNEE(S): Aarhus Amt., Hojbjerg, DENMARK (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002028764	A1	20020307
APPLICATION INFO.:	US 2001-928832	A1	20010814 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-1317	20000904
	US 2000-237715P	20001005 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BROWDY AND NEIMARK, P.L.L.C., 624 Ninth Street, N.W., Washington, DC, 20001	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	3074	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPATFULL on STN  
TI Amylin activity assays  
AB Novel methods for use in identifying or assaying compounds which can simulate the ability of amylin to cause hyperlactemia and hyperglycemia in in vivo biological models, or for use in evaluating the potency of compounds known or suspected to simulate these actions of amylin, which involve introducing test samples into in vivo test systems and determining the presence or amount of a rise in lactate, or determining the presence or amount of a rise in lactate and a rise in glucose, following test sample administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:43755 USPATFULL  
TITLE: Amylin activity assays  
INVENTOR(S): Young, Andrew A., San Diego, CA, United States  
Cooper, Garth J. S., Solana Beach, CA, United States  
Rink, Timothy J., La Jolla, CA, United States  
PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6048514		20000411
APPLICATION INFO.:	US 1995-422747		19950414 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-88629, filed on 6 Jul 1993, now abandoned which is a continuation of Ser. No. US 1991-666527, filed on 8 Mar 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-640478, filed on 10 Jan 1991, now patented, Pat. No. US 5234906		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Russel, Jeffrey E.		
LEGAL REPRESENTATIVE:	Lyon & Lyon LLP		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	1915		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L4 ANSWER 7 OF 10 USPATFULL on STN

TI Insulin receptor

AB Insulin receptor is purified in accordance with this invention to a level sufficient to enable amino acid sequencing thereof. DNA encoding insulin receptor is provided, as well as methods for synthesizing insulin receptor or its mutant in heterologous host cells transformed with vectors containing such DNA. Knowledge of the amino acid sequence for insulin receptor enables the preparation of novel immunogenic conjugates and antibodies raised against such conjugates. Novel therapeutically useful forms of the insulin receptor and anti-receptor antibodies are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 88:48719 USPATFULL

TITLE: Insulin receptor

INVENTOR(S): Bell, John R., San Francisco, CA, United States  
Ramachandran, Janakiraman, Palo Alto, CA, United States  
Ullrich, Axel, San Francisco, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4761371		19880802
APPLICATION INFO.:	US 1985-700776		19850212 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wiseman, Thomas G.		
ASSISTANT EXAMINER:	Seidman, Stephanie		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	1144		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

TI Improving insulin therapy: Achievements and challenges.

AB Microvascular complications of diabetes can be forestalled by effective glycemic control. However, the inherent limitations of standard subcutaneous insulins reduce their ability to control glycemia without risk of significant **hypoglycemia** and hyperinsulinemia. **Hypoglycemia** is unacceptable for most patients and may be dangerous. Hyperinsulinemia is undesirable because it causes weight gain and it has a putative association with atherosclerosis. This paper summarizes the major historical improvements in insulin therapy, and calls attention to the fact that none of the presently available commercial preparations in any combination is capable of simulating the profile of normal insulin secretion - the latter being regarded as the most effective means of normalizing glycemia. For this reason, a variety of new approaches to simulating the pharmacokinetics or glucodynamics of insulin secretion are under investigation. Fast-acting insulin analogues suitable for subcutaneous injection have been developed and appear to mimic the physiological insulin response more closely than standard insulins. Less progress has been made with basal insulins. Intravenous insulin has pharmacodynamic advantages but practical disadvantages of administration. Nasal insulin would be an attractive **treatment** modality only if its bioavailability could be significantly increased and its safety assured. Other interventions which improve glucose metabolism without necessarily simulating normal insulin secretion are under investigation. These include biosynthetic human C-peptide, insulin-like growth factor-1 and glucagon-like peptide 1 (7-36 amide).

ACCESSION NUMBER: 94381559 EMBASE

DOCUMENT NUMBER: 1994381559

TITLE: Improving insulin therapy: Achievements and challenges.  
AUTHOR: Galloway J.A.; Chance R.E.  
CORPORATE SOURCE: Lilly Research Laboratories, Lilly Corporate  
Center, Indianapolis, IN 46285, United States  
SOURCE: Hormone and Metabolic Research, (1994) 26/12 (591-598).  
ISSN: 0018-5043 CODEN: HMMRA2  
COUNTRY: Germany  
DOCUMENT TYPE: Journal; Conference Article  
FILE SEGMENT: 003 Endocrinology  
006 Internal Medicine  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L4 ANSWER 9 OF 10 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Composition useful for the **treatment** of diabetes in a human or  
other mammal or for preventing **hypoglycemia** in diabetes patient  
treated with insulin and who is not suffering from hypoglycemic symptoms  
comprises insulin and glucagon.  
AN 2004-543797 [52] WPIDS  
AB WO2004060387 A UPAB: 20040813  
NOVELTY - A pharmaceutical composition comprises insulin and glucagon for  
controlling diabetes and preventing **hypoglycemia** in a human or  
other mammal.  
DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an  
infusion pump containing both insulin and glucagon.  
ACTIVITY - Antidiabetic.  
A mixture of insulin and glucagon (1.5 %) (optionally modified  
release glucagon) was administered to the patient suffering from diabetes  
(35 years) and using insulin therapy from the time of diagnosis using pump  
(for both basal and prandial insulin). The results showed protection from  
**hypoglycemia** over the period of susceptibility as required.  
MECHANISM OF ACTION - **Insulin agonist**; Glucagon  
agonist.  
USE - In infusion pump; for the **treatment** of diabetes in a  
human or other mammal; for preventing **hypoglycemia** in diabetes  
patient treated with insulin and who is not suffering from hypoglycemic  
symptoms (all claimed).  
ADVANTAGE - The composition controls and treats diabetes while  
reducing or eliminating the risk of insulin-induced **hypoglycemia**  
. The composition maintains blood glucose levels that is, neither  
hyperglycemic nor hypoglycemic; prevents or reduces the frequency and  
severity of **hypoglycemia** in insulin-treated diabetic patients  
(both type 1 and type 2); can used to replenish or restore the abnormally  
low glucagons responses often coincident with insulin administration, thus  
preventing **hypoglycemia**. The composition, containing the insulin  
and glucagon are combined in a molar ratio that optimize glycemic  
management and attenuate the incidence of or prevent **hypoglycemia**

Dwg.0/7

ACCESSION NUMBER: 2004-543797 [52] WPIDS  
DOC. NO. CPI: C2004-199555  
TITLE: Composition useful for the **treatment** of  
diabetes in a human or other mammal or for preventing  
**hypoglycemia** in diabetes patient treated with  
insulin and who is not suffering from hypoglycemic  
symptoms comprises insulin and glucagon.  
DERWENT CLASS: B04  
INVENTOR(S): GREEN, D T; HENRY, R R  
PATENT ASSIGNEE(S): (DIOB-N) DIOBEX INC  
COUNTRY COUNT: 107  
PATENT INFORMATION:

PATENT NO      KIND DATE      WEEK      LA      PG

-----  
 WO 2004060387 A1 20040722 (200452)\* EN 55  
 RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE  
 LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE  
 DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG  
 KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM  
 PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US  
 UZ VC VN YU ZA ZM ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004060387	A1	WO 2003-US41103	20031223

PRIORITY APPLN. INFO: US 2003-470346P 20030513; US  
 2002-436735P 20021227; US  
 2003-454972P 20030314

L4 ANSWER 10 OF 10 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN  
 TI Composition for **treatment** of diabetes with reduced side effects  
 comprises an insulin sensitizer in combination with an anorectic.  
 AN 2000-147239 [13] WPIDS  
 AB WO 200000195 A UPAB: 20000313  
 NOVELTY - A pharmaceutical composition comprises an insulin sensitizer in  
 combination with an anorectic.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:

(1) a method for reducing the side effects of an insulin sensitizer  
 and/or an anorectic administered to a diabetic comprising administering an  
 effect amount of them;

(2) a method for preventing or treating diabetes and impaired glucose  
 tolerance in a mammal by administering to the mammal the sensitizer in  
 combination with an anorectic.

ACTIVITY - Antidiabetic; Anorectic.

The effects of concomitant administration of pioglitazone  
 hydrochloride and mazindol in non-insulin-dependent diabetic mellitus  
 (NIDDM) patients were studied. When pioglitazone hydrochloride (45mg/day  
 p.o.) was concomitantly administered to an NIDDM patient under  
**treatment** with mazindol (1.0mg/day p.o.) over the period of 8  
 weeks, fasting blood sugar decreased by 70 mg/dl, HbA1c decreased by 2%  
 and body weight decreased by 1.0 kg.

MECHANISM OF ACTION - **Insulin-Agonist.**

USE - The composition is useful for preventing and treating diabetes,  
 diabetic complications and for treating impaired glucose tolerance. The  
 composition possesses an increased blood sugar lowering action, blood  
 lipid lowering action or blood insulin lowering action as compared with  
 administration of an insulin sensitizer or an anorectic alone.

ADVANTAGE - Use of the present composition in combination with  
 insulin enables reduction of the amount of insulin used when compared with  
 the amount used at the time of administration of insulin alone. Therefore,  
 risk of blood vessel complication and **hypoglycemia** induction is  
 low.

Dwg.0/0

ACCESSION NUMBER: 2000-147239 [13] WPIDS  
 DOC. NO. CPI: C2000-046089  
 TITLE: Composition for **treatment** of diabetes with  
 reduced side effects comprises an insulin sensitizer in  
 combination with an anorectic.  
 DERWENT CLASS: B03  
 INVENTOR(S): ODAKA, H; YAMANE, M  
 PATENT ASSIGNEE(S): (TAKE) TAKEDA CHEM IND LTD; (ODAK-I) ODAKA H; (YAMA-I)  
 YAMANE M

COUNTRY COUNT: 86  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000000195	A1	20000106	(200013)*	EN	43
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ UG ZW					
W: AE AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GD GE HR HU ID IL IN					
IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI					
SK SL TJ TM TR TT UA US UZ VN YU ZA					
JP 2000080047	A	20000321	(200025)		14
AU 9942914	A	20000117	(200026)		
BR 9911656	A	20010320	(200123)		
NO 2000006630	A	20010226	(200123)		
EP 1093370	A1	20010425	(200124)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
CN 1305376	A	20010725	(200164)		
KR 2001043455	A	20010525	(200168)		
US 6329403	B1	20011211	(200204)		
ZA 2000006262	A	20020130	(200217)		54
MX 2000010582	A1	20010501	(200227)		
US 2002086885	A1	20020704	(200247)		
AU 754740	B	20021121	(200305)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000000195	A1	WO 1999-JP3496	19990629
JP 2000080047	A	JP 1999-183299	19990629
AU 9942914	A	AU 1999-42914	19990629
BR 9911656	A	BR 1999-11656	19990629
		WO 1999-JP3496	19990629
NO 2000006630	A	WO 1999-JP3496	19990629
		NO 2000-6630	20001222
EP 1093370	A1	EP 1999-957622	19990629
		WO 1999-JP3496	19990629
CN 1305376	A	CN 1999-807133	19990629
KR 2001043455	A	KR 2000-712502	20001108
US 6329403	B1	WO 1999-JP3496	19990629
		US 1999-380059	19990825
ZA 2000006262	A	ZA 2000-6262	20001102
MX 2000010582	A1	MX 2000-10582	20001027
US 2002086885	A1 Div ex	WO 1999-JP3496	19990629
	Div ex	US 1999-380059	19990825
		US 2001-36208	20011229
AU 754740	B	AU 1999-42914	19990629

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9942914	A Based on	WO 2000000195
BR 9911656	A Based on	WO 2000000195
EP 1093370	A1 Based on	WO 2000000195
US 6329403	B1 Based on	WO 2000000195
AU 754740	B Previous Publ. Based on	AU 9942914 WO 2000000195

PRIORITY APPLN. INFO: JP 1998-183700 19980630

=> d 17 ti abs ibib tot

L7 ANSWER 1 OF 32 MEDLINE on STN

TI Glucagon replacement via micro-osmotic pump corrects **hypoglycemia** and alpha-cell hyperplasia in prohormone convertase 2 knockout mice.

AB Prohormone convertase 2 (PC2) plays an essential role in the processing of proglucagon to mature active glucagon in pancreatic alpha-cells (J Biol Chem 276:27197-27202, 2001). Mice lacking PC2 demonstrate multiple defects, including chronic mild **hypoglycemia** and dramatic hyperplasia of the pancreatic alpha-cells. To define the contribution of mature glucagon deficiency to the **hypoglycemia** and alpha-cell hyperplasia, we have attempted to correct the defects by delivery of exogenous glucagon by micro-osmotic pumps. Intraperitoneal delivery of 0.5 microg glucagon/h in PC2(-/-) mice resulted in the normalization of blood glucose concentrations. Islet remodeling through the loss of hyperplastic alpha-cells was evident by day 11 after pump implantation; by 25 days postimplantation, PC2(-/-) islets were indistinguishable from wild-type islets. These rapid changes were brought about by induction of apoptosis in the alpha-cell population. Morphological normalization of islets was also accompanied by marked downregulation of endogenous preproglucagon gene expression, but with little or no change in the level of preproinsulin gene expression. Exogenous glucagon delivery also normalized hepatic expression of the gluconeogenic enzyme PEPCK. These results demonstrate that the lack of mature glucagon in PC2(-/-) mice is responsible for the aberrant blood glucose levels, islet morphology, and gene expression, and they confirm the role of glucagon as a tonic **insulin antagonist** in regulating glycemia.

ACCESSION NUMBER: 2002132506 MEDLINE

DOCUMENT NUMBER: PubMed ID: 11812747

TITLE: Glucagon replacement via micro-osmotic pump corrects **hypoglycemia** and alpha-cell hyperplasia in prohormone convertase 2 knockout mice.

AUTHOR: Webb Gene C; Akbar Murtaza S; Zhao Chongjian; Swift Hewson H; Steiner Donald F

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois, USA.

CONTRACT NUMBER: DK13914 (NIDDK)

DK2059 (NIDDK)

SOURCE: Diabetes, (2002 Feb) 51 (2) 398-405.  
Journal code: 0372763. ISSN: 0012-1797.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 200203

ENTRY DATE: Entered STN: 20020301

Last Updated on STN: 20021026

Entered Medline: 20020315

L7 ANSWER 2 OF 32 MEDLINE on STN

TI Insulin antagonism: a novel role for human serum transferrin.

AB We have purified alpha2-glycoprotein (alpha2-GP), an **insulin antagonist** from human plasma which is induced by growth hormone (GH), and shown that pure alpha2-GP is a potent antagonist of severe insulin-induced **hypoglycemia**, producing acute hyperglycemia in intact rats and ketonuria in diabetic rats. The N-terminal amino acid sequence of alpha2-GP and the reactivity of alpha2-GP with an antitransferrin monoclonal antibody show that alpha2-GP is identical to human serum transferrin. Furthermore, pure human serum transferrin and non-glycosylated recombinant human transferrin reproduce the **insulin antagonist** effects of alpha2-GP in rats, whereas ovotransferrin shows no such effect. The neutralization of the insulin antagonism of human serum transferrin by an anti-transferrin monoclonal antibody shows that transferrin has a new function as a potent **insulin antagonist**. This novel role for human serum

transferrin in the regulation of glucose metabolism provides a reasonable mechanism for the diabetogenic effect of GH, and has important implications for the etiology and progression of diabetes.

ACCESSION NUMBER: 1998226502 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 9566850  
TITLE: Insulin antagonism: a novel role for human serum transferrin.  
AUTHOR: Vargas L; Kawada M E; Bazaes S; Karplus P A; Faerman C H  
CORPORATE SOURCE: Department of Cell and Molecular Biology, Pontifical Catholic University of Chile, Santiago.  
CONTRACT NUMBER: 1 P01 GM4887 (NIGMS)  
SOURCE: Hormone and metabolic research. Hormon- und Stoffwechselforschung. Hormones et metabolisme, (1998 Mar) 30 (3) 113-7.  
Journal code: 0177722. ISSN: 0018-5043.  
PUB. COUNTRY: GERMANY: Germany, Federal Republic of  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199806  
ENTRY DATE: Entered STN: 19980618  
Last Updated on STN: 19980618  
Entered Medline: 19980608

L7 ANSWER 3 OF 32 MEDLINE on STN

TI Demonstration of heterogeneity of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing.  
AB With isoelectric focusing, we examined heterogeneity of autoantibodies to insulin receptors in serums of two patients with insulin-resistant diabetes and one patient with **hypoglycemia**. Immunoglobulins were prepared by ammonium sulfate precipitation and ion-exchange chromatography with DEAE-Sephadex and subjected to isoelectric focusing for separation into 30 fractions. The fractions were tested for their ability to inhibit <sup>125</sup>I-labeled insulin binding to human placental membranes, immunoprecipitate solubilized insulin receptor cross-linked with <sup>125</sup>I-insulin, and mimic or inhibit the action of insulin in rat adipocytes. The results varied among the three patients. In the first patient, inhibition of <sup>125</sup>I-insulin-binding activity (IBA) and insulin-receptor-precipitating activity (IPA) were distributed almost identically, but the distribution of insulinlike bioactivity (ILBA) was somewhat different. In the second patient, some fractions exhibited potent IBA without IPA, and these fractions inhibited the action of insulin in rat adipocytes. In the third patient, all of the isoelectric fractions showed IBA without IPA and were insulin antagonists. These observations indicate that some patients have antibodies with pure **insulin-antagonist** properties and provide further evidence that autoantibodies to insulin receptors are polyclonal and recognize different antigenic sites on insulin-receptor molecules. The findings also suggest that the ability of antibodies to elicit ILBA is linked to the ability to immunoprecipitate <sup>125</sup>I-insulin-cross-linked and solubilized receptors, whereas antibodies that only inhibit insulin binding behave as insulin antagonists.

ACCESSION NUMBER: 89357274 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 2767337  
TITLE: Demonstration of heterogeneity of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing.  
AUTHOR: Tsushima T; Omori Y; Murakami H; Hirata Y; Shizume K  
CORPORATE SOURCE: Second Department of Medicine, Tokyo Women's Medical College, Japan.  
SOURCE: Diabetes, (1989 Sep) 38 (9) 1090-6.  
Journal code: 0372763. ISSN: 0012-1797.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 198910  
ENTRY DATE: Entered STN: 19900309  
Last Updated on STN: 20000303  
Entered Medline: 19891003

L7 ANSWER 4 OF 32 MEDLINE on STN

TI Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.  
AB Continuous, low dose, insulin infusion in conscious dogs produced moderate **hypoglycemia** but only a transient fall in glucose production that rose towards preinfusion levels 20 to 30 min before any detectable increase in plasma counterregulatory hormones. Addition of epinephrine or glucagon to the insulin infusion prevented the fall in glucose production throughout the experiment but only partially diminished the hypoglycemic response. When **hypoglycemia** was prevented by a variable glucose infusion, neither epinephrine nor glucagon was able to counteract the suppressive effect of insulin on glucose output. These findings suggest that a fall in blood glucose per se may reverse insulin-induced inhibition of glucose production independent of a rise in counterregulatory hormones and that the **insulin antagonist** effect of counter-regulatory hormones is modulated, at least in part, by blood glucose concentration.

ACCESSION NUMBER: 79192270 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 446911  
TITLE: Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.  
AUTHOR: Sacca L; Cryer P E; Sherwin R S  
SOURCE: Diabetes, (1979 Jun) 28 (6) 533-6.  
Journal code: 0372763. ISSN: 0012-1797.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 197908  
ENTRY DATE: Entered STN: 19900315  
Last Updated on STN: 19900315  
Entered Medline: 19790816

L7 ANSWER 5 OF 32 MEDLINE on STN

TI Insulin therapy and behaviors of **insulin antagonist** hormones, with special reference to the reactions of growth hormone and cortisol during the hypoglycemic stage in juvenile diabetes.

ACCESSION NUMBER: 79064260 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 719944  
TITLE: Insulin therapy and behaviors of **insulin antagonist** hormones, with special reference to the reactions of growth hormone and cortisol during the hypoglycemic stage in juvenile diabetes.  
AUTHOR: Egi S  
SOURCE: Horumon to rinsho. Clinical endocrinology, (1978 Sep) 26 (9) 947-51.  
Journal code: 0420561. ISSN: 0045-7167.  
PUB. COUNTRY: Japan  
DOCUMENT TYPE: (CASE REPORTS)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Japanese  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 197902  
ENTRY DATE: Entered STN: 19900314  
Last Updated on STN: 19900314  
Entered Medline: 19790223

L7 ANSWER 6 OF 32 MEDLINE on STN  
TI Chlorpropamide-induced **hypoglycemia**: successful treatment with diazoxide.  
AB A healthy adolescent boy was treated on two occasions for an overdose of chlorpropamide (Diabinese). Glucose therapy alone was not sufficient to control the **hypoglycemia**, but the administration of glucose plus diazoxide raised the blood sugar to supranormal levels. A bolus of intravenous glucagon briefly raised the blood sugar level to within normal limits, increased the blood ketones but also augmented insulin secretion. An overdose of sulfonylurea may cause prolonged and fatal **hypoglycemia**. Rational therapy, both in diabetic and normal persons, is glucose plus an "**insulin antagonist**." The administration of diazoxide was effective in our patient, substantially reducing the plasma insulin level; this agent may be the "**insulin -antagonist**" of choice for use in sulfonylurea-induced **hypoglycemia**.

ACCESSION NUMBER: 78058323 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 930951  
TITLE: Chlorpropamide-induced **hypoglycemia**: successful treatment with diazoxide.  
AUTHOR: Johnson S F; Schade D S; Peake G T  
SOURCE: American journal of medicine, (1977 Nov) 63 (5) 799-804.  
Journal code: 0267200. ISSN: 0002-9343.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (CASE REPORTS)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 197801  
ENTRY DATE: Entered STN: 19900314  
Last Updated on STN: 19900314  
Entered Medline: 19780127

L7 ANSWER 7 OF 32 MEDLINE on STN  
TI The relative roles of calcium, phosphorus, and parathyroid hormone in glucose- and tolbutamide-mediated insulin release.  
AB The relative contributions of Ca++, phosphorus, and parathyroid hormone (PTH) on insulin secretion were evaluated in three groups of dogs. Dogs were studied with glucose infusions (group I) or standard intravenous glucose tolerance tests (IVGTT) (group II) before and after the development of diet-induced hypophosphatemia. Mean serum phosphorus levels for both groups fell from 4.1 to 1.1 mg/100 ml. Animals in group I demonstrated a fall in glucose disappearance rates (Kg) from 5.3+/-0.6% min to 3.5+/-0.5% after induction of hypophosphatemia (P less than 0.001). Mean insulin response was significantly greater in the hypophosphatemic animals than in controls in this group. In group II animals, mean insulin areas obtained during the IVGTT increased from 1,426+/-223 to 2,561+/-141 muU/ml/60 min after induction of hypophosphatemia, and were unaffected by Ca++ or PTH administration. Ca++ administration, but not hypophosphatemia or PTH infusion, increased significantly the mean insulin response to tolbutamide. Secondary hyperparathyroidism was induced by dietary manipulation in four dogs (group III). Mean PTH values increased from 71.4+/-2.1 to 3,012+/-372 pg/ml (P less than 0.001). Mean insulin response to an IVGTT was similar to group III animals, but increased from 1,352+/-128 to 1,894+/-360 muU/ml/60 min after the excessive dietary phosphorus was reduced for 3 mo, and plasma phosphorus fell from 3.2+/-0.1 to 2.8+/-0.3 mg/100 ml. PTH values decreased to 647+/-53 pg/ml. The insulin response to tolbutamide was comparable to that in group II animals, but increased significantly after calcium administration. Immunoreactive insulin disappearance rates were unaffected by hypophosphatemia or diet-induced secondary hyperparathyroidism. These data demonstrate that hypophosphatemia is associated with an augmented glucose-stimulated insulin release, without any effect on tolbutamide-stimulated insulin release. Hypercalcemia produces an



augmented tolbutamide-stimulated insulin release with no apparent effect on glucose-stimulated insulin release. Finally, PTH does not appear to be an **insulin antagonist** and has no apparent effect on either glucose- or tolbutamide-stimulated insulin release in animals with dietary-induced secondary hyperparathyroidism.

ACCESSION NUMBER: 76260562 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 956371  
TITLE: The relative roles of calcium, phosphorus, and parathyroid hormone in glucose- and tolbutamide-mediated insulin release.  
AUTHOR: Harter H R; Santiago J V; Rutherford W E; Slatopolsky E; Klahr S  
SOURCE: Journal of clinical investigation, (1976 Aug) 58 (2) 359-67.  
Journal code: 7802877. ISSN: 0021-9738.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 197610  
ENTRY DATE: Entered STN: 19900313  
Last Updated on STN: 19900313  
Entered Medline: 19761029

L7 ANSWER 8 OF 32 MEDLINE on STN

TI Letter: The effect of contraceptive steroids on carbohydrate metabolism.  
AB Comments are made on a short review on the effect of contraceptive steroids on carbohydrate metabolism which appeared previously. Intravenous tolbutamide tolerance tests were performed on 13 normal women and 8 hypopituitary patients before and 3 and 6 months after starting on an oral contraceptive agent (OCA) containing 50 mcg mestranol and 1 mg norethindrone. The control subjects demonstrated a significant impairment of the glucose fall after tolbutamide and an enhancement of the growth hormone (GH) response to the resultant **hypoglycemia** while on the OCA. The pituitary-deficient patients showed no change in their glucose response to tolbutamide after starting OCA and they had minimal GH secretion as expected. 5 additional normal females on a variety of OCAs had a significant 3-fold increase in GH concentrations after moderate exercise as compared with 5 other women using other forms of contraception. The peripheral tissues of women on OCAs were exposed to higher levels of GH throughout the day. The data seemed to implicate the anterior pituitary gland, and it was postulated that the estrogen-induced secretion of GH, a potent **insulin antagonist**, was responsible for the effects of OCAs on carbohydrate metabolism. It is concluded through laboratory investigations that there is good evidence to support the role of estrogens alone in causing deterioration of glucose tolerance. This contradicts the review in which it was concluded that carbohydrate metabolism in younger women was unaffected by estrogens alone but will deteriorate in response to a combination of estrogen and nortestosterone progestins.

ACCESSION NUMBER: 74258967 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 4834911  
TITLE: Letter: The effect of contraceptive steroids on carbohydrate metabolism.  
AUTHOR: Davidson M B  
SOURCE: Metabolism: clinical and experimental, (1974 Jul) 23 (7) 687-90.  
Journal code: 0375267. ISSN: 0026-0495.  
Report No.: PIP-741979; POP-00022298.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals; Population  
ENTRY MONTH: 197408

ENTRY DATE: Entered STN: 19900310  
Last Updated on STN: 20021101  
Entered Medline: 19740828

L7 ANSWER 9 OF 32 MEDLINE on STN  
TI Role of synalbumin **insulin antagonist** in pathogenesis  
of diabetes mellitus.  
ACCESSION NUMBER: 70294301 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 4918251  
TITLE: Role of synalbumin **insulin antagonist**  
in pathogenesis of diabetes mellitus.  
AUTHOR: Davidson M B; Poffenbarger P L  
SOURCE: Metabolism: clinical and experimental, (1970 Sep) 19 (9)  
668-86. Ref: 115  
Journal code: 0375267. ISSN: 0026-0495.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 197011  
ENTRY DATE: Entered STN: 19900101  
Last Updated on STN: 19900101  
Entered Medline: 19701106

L7 ANSWER 10 OF 32 USPATFULL on STN  
TI Insulin-associated peptides with effects on cerebral health  
AB The present invention provides compositions and methods for ameliorating  
neurological, attention, or memory disorders and improving learning and  
cognition through the delivery of insulin A-chain and analogs thereof to  
a subject. Insulin A-chain, peptides comprising the 21 amino acid  
sequence GIVEQ CCASV CSLYQ LENYC N (SEQ ID NO:1), and functional analogs  
thereof are disclosed to modulate neurological activity when  
administered to a subject. The methods of the invention can be used to  
prevent or treat neurological disorders as well as improve memory  
retention and acquisition. The invention includes pharmaceutical  
compositions comprising a therapeutically or prophylactically effective  
amount of insulin A-chain peptide or a functional analogs thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:19356 USPATFULL  
TITLE: Insulin-associated peptides with effects on cerebral  
health  
INVENTOR(S): During, Matthew J., Philadelphia, PA, UNITED STATES  
Haile, Colin N., Katy, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014660	A1	20040122
APPLICATION INFO.:	US 2003-430545	A1	20030506 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-378318P	20020506 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	2477	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 32 USPATFULL on STN

TI Treatment of acute coronary syndrome with GLP-1

AB The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2431 USPATFULL

TITLE: Treatment of acute coronary syndrome with GLP-1

INVENTOR(S): Coolidge, Thomas R., Falls Village, CT, UNITED STATES  
Ehlers, Mario, Lincoln, NE, UNITED STATES

PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc., San Diego, CA, UNITED STATES, 68524 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002454	A1	20040101
APPLICATION INFO.:	US 2002-322839	A1	20021218 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-859804, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205239P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ARNOLD & PORTER, Attn: IP Docketing Department, Room 1126B, 555 Twelfth Street, NW, Washington, DC, 20004-1206	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1204	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 32 USPATFULL on STN

TI Novel polypeptide of protein p140 and DNAs encoding it

AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment for the currently said the prevention and/or treatment method; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylation of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent.

Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244456 USPATFULL  
 TITLE: Novel polypeptide of protein p140 and DNAs encoding it  
 INVENTOR(S): Tajima, Hisao, Osaka, JAPAN  
 Kitagawa, Koichiro, Osaka, JAPAN  
 Ohno, Hiroyuki, Osaka, JAPAN  
 PATENT ASSIGNEE(S): ONO PHARMACEUTICAL CO., LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170865	A1	20030911
APPLICATION INFO.:	US 2002-187958	A1	20020703 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-558340, filed on 26 Apr 2000, GRANTED, Pat. No. US 6432913 Division of Ser. No. US 1998-192435, filed on 8 Jan 1998, GRANTED, Pat. No. US 6303320 Division of Ser. No. US 1995-571785, filed on 13 Dec 1995, GRANTED, Pat. No. US 5804411 Division of Ser. No. US 1994-348143, filed on 23 Nov 1994, GRANTED, Pat. No. US 5506205		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC, 20037-3213	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1757	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 13 OF 32 USPATFULL on STN  
 TI Blood glucose level control  
 AB A pancreatic controller, comprising:

at least one electrode adapted for electrifying at least a portion of a pancreas; and

a controller programmed to electrify said electrode so as to positively control at least the effect of at least two members of a group consisting of blood glucose level, blood insulin level and blood level of another pancreatic hormone. In one example, the controller controls insulin, glucagon and/or glucose blood levels.

ACCESSION NUMBER: 2003:79535 USPATFULL  
 TITLE: Blood glucose level control  
 INVENTOR(S): Darvish, Nissim, Hof-Hacarmel, ISRAEL  
 Harel, Tami, Haifa, ISRAEL  
 Felsen, Bella, Haifa, ISRAEL  
 Glasberg, Offer, Haifa, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055464	A1	20030320
APPLICATION INFO.:	US 2002-237263	A1	20020905 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-IL566, filed on 13 Sep 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-IL132	20000305
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: William H. Dippert, Esq., Reed Smith LLP, 29th Floor,  
599 Lexington Avenue, New York, NY, 10022-7650  
NUMBER OF CLAIMS: 55  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 27 Drawing Page(s)  
LINE COUNT: 2529

L7 ANSWER 14 OF 32 USPATFULL on STN

TI Polypeptide of protein p140 and DNAs encoding it

AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment for the currently said the prevention and/or treatment method; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylation of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent.

Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:202054 USPATFULL  
TITLE: Polypeptide of protein p140 and DNAs encoding it  
INVENTOR(S): Tajima, Hisao, Osaka, JAPAN  
Kitagawa, Koichiro, Osaka, JAPAN  
Ohno, Hiroyuki, Osaka, JAPAN  
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6432913	B1	20020813
APPLICATION INFO.:	US 2000-558340		20000426 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-192435, filed on 8 Jan 1998, now patented, Pat. No. US 6303320 Division of Ser. No. US 1995-571785, filed on 13 Dec 1995, now patented, Pat. No. US 5804411 Division of Ser. No. US 1994-348143, filed on 23 Nov 1994, now patented, Pat. No. US 5506205		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Mitra, Rita	
LEGAL REPRESENTATIVE:	Sughrue Mion, PLLC	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1678	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 32 USPATFULL on STN  
TI Treatment of acute coronary syndrome with GLP-1  
AB The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:199097 USPATFULL  
TITLE: Treatment of acute coronary syndrome with GLP-1  
INVENTOR(S): Coolidge, Thomas R., Falls Village, CT, UNITED STATES  
Ehlers, Mario, Lincoln, NE, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002107206	A1	20020808
	US 6706689	B2	20040316
APPLICATION INFO.:	US 2001-859804	A1	20010518 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205239P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W. Suite 500, Washington, DC, 20007-5109	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1101	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 32 USPATFULL on STN  
TI Polypeptide of protein P140 and DNAs encoding it  
AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the polypeptide; vector derived with the DNA; host cells transformed with the vector; antibody of the polypeptide; pharmaceutical composition containing the peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the protein p140; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate protein p140, as active ingredient and the screening methods of the prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:178824 USPATFULL  
TITLE: Polypeptide of protein P140 and DNAs encoding it  
INVENTOR(S): Tajima, Hisao, Osaka, Japan  
Kitagawa, Koichiro, Osaka, Japan  
Ohno, Hiroyuki, Osaka, Japan

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303320	B1	20011016
APPLICATION INFO.:	US 1998-192435		19980108 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-571785, filed on 13 Dec 1995, now patented, Pat. No. US 5804411 Division of Ser. No. US 1994-348143, filed on 23 Nov 1994, now patented, Pat. No. US 5506205		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Mitra, Rita	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas, PLLC	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1169	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 17 OF 32 USPATFULL on STN

TI Nucleic acid encoding a transcription factor, IDX-1

AB The invention features a novel recombinant polypeptide that transactivates the somatostatin promoter, the polypeptide being present in pancreatic duct cells and not present in pancreatic  $\alpha$ -cells, the polypeptide being encoded by a gene which encodes a protein on the order of 31 kd.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:47834 USPATFULL

TITLE: Nucleic acid encoding a transcription factor, IDX-1

INVENTOR(S): Habener, Joel F., Newton Highlands, MA, United States  
Miller, Christopher P., Arlington, MA, United States

PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6210960	B1	20010403
APPLICATION INFO.:	US 1996-751344		19961119 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-202044, filed on 23 Feb 1994, now patented, Pat. No. US 5858973		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Pak, Michael		
LEGAL REPRESENTATIVE:	Palmer & Dodge, LLP, Williams, Kathleen		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	33 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1642		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 18 OF 32 USPATFULL on STN

TI Use of human transferrin in controlling insulin levels

AB The present invention relates to the use of transferrin in controlling insulin levels. Transferrin can disrupt insulin:receptor interactions in mammalian cells, may be used in mammals to treat **hypoglycemia**, may also be used to inhibit production of insulin by mammalian cells,

and can decrease the serum insulin levels in a mammal. The invention further provides methods for identifying compounds which modulate the effect of transferrin on insulin signal transduction. Pharmaceutical compositions containing transferrin are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:67782 USPATFULL  
TITLE: Use of human transferrin in controlling insulin levels  
INVENTOR(S): Vargas, Luis A., Santiago, Chile  
Faerman, Carlos H., Ithaca, NY, United States  
Karplus, P. Andrew, Ithaca, NY, United States  
PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6069193		20000530
APPLICATION INFO.:	US 1998-167853		19981007 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-585355, filed on 11 Jan 1996, now patented, Pat. No. US 5849293, issued on 15 Dec 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kemmerer, Elizabeth		
ASSISTANT EXAMINER:	Basi, Nirmal S.		
LEGAL REPRESENTATIVE:	Nixon Peabody LLP		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	902		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 32 USPATFULL on STN  
TI Transcription factor and uses therefor  
AB The invention features a novel recombinant polypeptide that transactivates the somatostatin promoter, the polypeptide being present in pancreatic duct cells and not present in pancreatic  $\alpha$ -cells, the polypeptide being encoded by a gene which encodes a protein on the order of 31 kd.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:4631 USPATFULL  
TITLE: Transcription factor and uses therefor  
INVENTOR(S): Habener, Joel F., Newton Highlands, MA, United States  
Miller, Christopher P., Arlington, MA, United States  
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5858973		19990112
APPLICATION INFO.:	US 1994-202044		19940223 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Hobbs, Lisa J.		
LEGAL REPRESENTATIVE:	Banner & Allegretti, Ltd.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	33 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1886		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 32 USPATFULL on STN



TI Use of human transferrin in controlling insulin levels  
AB The present invention relates to the use of transferrin in controlling insulin levels. Transferrin can disrupt insulin:receptor interactions in mammalian cells, may be used in mammals to treat **hypoglycemia**, may also be used to inhibit production of insulin by mammalian cells, and can decrease the serum insulin levels in a mammal. The invention further provides methods for identifying compounds which modulate the effect of transferrin on insulin signal transduction. Pharmaceutical compositions containing transferrin are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:156916 USPATFULL  
TITLE: Use of human transferrin in controlling insulin levels  
INVENTOR(S): Vargas, Luis A., Santiago, Chile  
Faerman, Carlos H., Ithaca, NY, United States  
Karplus, P. Andrew, Ithaca, NY, United States  
PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849293		19981215
APPLICATION INFO.:	US 1996-585355		19960111 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Walsh, Stephen		
ASSISTANT EXAMINER:	Basi, Nirmal S.		
LEGAL REPRESENTATIVE:	Nixon, Hargrave, Devans & Doyle LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	893		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 32 USPATFULL on STN

TI Polypeptide of protein P140 and DNAs encoding it  
AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment of diabetes, agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only to improve the diabetes-derived hypoglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:108245 USPATFULL  
TITLE: Polypeptide of protein P140 and DNAs encoding it  
INVENTOR(S): Tajima, Hisao, Osaka, Japan  
Kitagawa, Koichiro, Osaka, Japan  
Ohno, Hiroyuki, Osaka, Japan  
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804411		19980908
APPLICATION INFO.:	US 1995-571785		19951213 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-348143, filed on 23 Nov 1994, now patented, Pat. No. US 5506205		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wax, Robert A.	
ASSISTANT EXAMINER:	Lau, Kawai	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas, PLLC	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1594	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 32 USPATFULL on STN

TI Polypeptide of protein p140 and DNAs encoding it

AB The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector comprising the DNA; host cells transformed with the vector; antibody against the polypeptide; pharmaceutical compositions containing the peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate protein p140, as active ingredient and screening methods for the prevention and/or treatment agent.

Tyrosine phosphorylation of protein p140 is an essential step in the induction of **hypoglycemia** by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only to improves the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:29534 USPATFULL

TITLE: Polypeptide of protein p140 and DNAs encoding it

INVENTOR(S): Tajima, Hisao, Osaka, Japan  
Kitagawa, Koichiro, Osaka, Japan  
Ohno, Hiroyuki, Osaka, Japan

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5506205		19960409
APPLICATION INFO.:	US 1994-348143		19941123 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-315806	19931124
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	

PRIMARY EXAMINER: Wax, Robert A.  
ASSISTANT EXAMINER: Lau, Kawai  
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas  
NUMBER OF CLAIMS: 2  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)  
LINE COUNT: 1556  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 32 USPATFULL on STN

TI Method of controlling diabetes mellitus

AB The use of precise dosages of insulin-plus-sugar in a method of controlling and/or treating diabetes is disclosed, including the steps of frequently testing both the blood sugar level and the urine sugar level of the diabetic patient; and administering insulin and/or sugar as required by the results of the blood and urine sugar tests. The amount of insulin and/or sugar administered is reviewed daily and modifications are made on a daily basis such that the patient over time will need little or no insulin. The present invention is also related to a method for controlling the out-of-control diabetic patient and to a method for reversing the negative effects already caused by diabetes. This method also avoids the side effects of insulin use such as **hypoglycemia** and hyperinsulinemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 95:47704 USPATFULL  
TITLE: Method of controlling diabetes mellitus  
INVENTOR(S): Shohet, Isaac H., 70-34 Kissena Blvd., Flushing, NY,  
United States 11367

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5420108		19950530
APPLICATION INFO.:	US 1992-943176		19920914 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Warden, Jill		
ASSISTANT EXAMINER:	Davenport, A. M.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2806		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 32 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin -

AN AAB07358 peptide DGENE

AB Type II diabetes mellitus (non-insulin-dependent diabetes mellitus) is caused by defective signal transduction by the insulin receptor, leading to insulin resistance and ultimately an increase in blood glucose levels. The present sequence is the amino-terminal sequence of human alpha2-glycoprotein (alpha2-GP, alpha2-inhibitor). Alpha2-GP is an **insulin antagonist**. The present sequence was used in sequence analysis and showed that alpha2-GP is in fact identical to human serum transferrin (hsTf). Transferrin is a glycoprotein which is needed for the transportation of iron in blood. Transferrin may be administered to type II diabetes mellitus patients due to its insulin antagonism effects.

ACCESSION NUMBER: AAB07358 peptide DGENE  
TITLE: Treating type II diabetes mellitus or **hypoglycemia**,  
and decreasing insulin production or serum insulin level  
comprises administering transferrin -  
INVENTOR: Karplus P A; Vargas L A; Faerman C H

PATENT ASSIGNEE: (CORR) CORNELL RES FOUND INC.  
PATENT INFO: US 6069193 A 20000530 16p  
APPLICATION INFO: US 1998-167853 19981007  
PRIORITY INFO: US 1996-585355 19960111  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2000-430142 [37]  
DESCRIPTION: Human alpha2-GP amino-terminal sequence # 2.

L7 ANSWER 25 OF 32 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin -  
AN AAB07357 peptide DGENE  
AB Type II diabetes mellitus (non-insulin-dependent diabetes mellitus) is caused by defective signal transduction by the insulin receptor, leading to insulin resistance and ultimately an increase in blood glucose levels. The present sequence is the amino-terminal sequence of human alpha2-glycoprotein (alpha2-GP, alpha2-inhibitor). Alpha2-GP is an **insulin antagonist**. The present sequence was used in sequence analysis and showed that alpha2-GP is in fact identical to human serum transferrin (hstf). Transferrin is a glycoprotein which is needed for the transportation of iron in blood. Transferrin may be administered to type II diabetes mellitus patients due to its insulin antagonism effects.

ACCESSION NUMBER: AAB07357 peptide DGENE  
TITLE: Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin -  
INVENTOR: Karplus P A; Vargas L A; Faerman C H  
PATENT ASSIGNEE: (CORR) CORNELL RES FOUND INC.  
PATENT INFO: US 6069193 A 20000530 16p  
APPLICATION INFO: US 1998-167853 19981007  
PRIORITY INFO: US 1996-585355 19960111  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2000-430142 [37]  
DESCRIPTION: Human alpha2-GP amino-terminal sequence # 1.

L7 ANSWER 26 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN  
TI Glucagon replacement via micro-osmotic pump corrects **hypoglycemia** and  $\alpha$ -cell hyperplasia in prohormone convertase 2 knockout mice.  
AB Prohormone convertase 2 (PC2) plays an essential role in the processing of proglucagon to mature active glucagon in pancreatic  $\alpha$ -cells (J Biol Chem 276:27197-27202, 2001). Mice lacking PC2 demonstrate multiple defects, including chronic mild **hypoglycemia** and dramatic hyperplasia of the pancreatic  $\alpha$ -cells. To define the contribution of mature glucagon deficiency to the **hypoglycemia** and  $\alpha$ -cell hyperplasia, we have attempted to correct the defects by delivery of exogenous glucagon by micro-osmotic pumps. Intraperitoneal delivery of 0.5  $\mu$ g glucagon/h in PC2(-/-) mice resulted in the normalization of blood glucose concentrations. Islet remodeling through the loss of hyperplastic  $\alpha$ -cells was evident by day 11 after pump implantation; by 25 days postimplantation, PC2(-/-) islets were indistinguishable from wildtype islets. These rapid changes were brought about by induction of apoptosis in the  $\alpha$ -cell population. Morphological normalization of islets was also accompanied by marked downregulation of endogenous preproglucagon gene expression, but with little or no change in the level of preproinsulin gene expression. Exogenous glucagon delivery also normalized hepatic expression of the gluconeogenic enzyme PEPCK. These results demonstrate that the lack of mature glucagon in PC2(-/-) mice is responsible for the aberrant blood glucose levels, islet morphology, and gene expression, and they confirm the role of glucagon as a tonic

**insulin antagonist** in regulating glycemia.

ACCESSION NUMBER: 2002255057 EMBASE  
TITLE: Glucagon replacement via micro-osmotic pump corrects **hypoglycemia** and  $\alpha$ -cell hyperplasia in prohormone convertase 2 knockout mice.  
AUTHOR: Webb G.C.; Akbar M.S.; Zhao C.; Swift H.H.; Steiner D.F.  
CORPORATE SOURCE: D.F. Steiner, MC1028, 5841 S. Maryland Ave., Chicago, IL 60637, United States. dfsteine@midway.uchicago.edu  
SOURCE: Diabetes, (2002) 51/2 (398-405).  
Refs: 37  
ISSN: 0012-1797 CODEN: DIAEAZ  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 003 Endocrinology  
029 Clinical Biochemistry  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L7 ANSWER 27 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

TI Insulin antagonism: A novel role for human serum transferrin.

AB We have purified  $\alpha$ 2-glycoprotein ( $\alpha$ 2-GP), an **insulin antagonist** from human plasma which is induced by growth hormone (GH), and shown that pure  $\alpha$ 2-GP is a potent antagonist of severe insulin-induced **hypoglycemia**, producing acute hyperglycemia in intact rats and in diabetic rats. The N- terminal amino acid sequence of  $\alpha$ 2-GP and the reactivity of  $\alpha$ 2-GP with an antitransferrin monoclonal antibody show that  $\alpha$ 2-GP is identical to human serum transferrin. Furthermore, pure human serum transferrin and non-glycosylated recombinant human transferrin reproduce the **insulin antagonist** effects of  $\alpha$ 2-GP in rats, whereas ovotransferrin shows no such effect. The neutralization of the insulin antagonism of human serum transferrin by an anti-transferrin monoclonal antibody shows that transferrin has a new function as a potent **insulin antagonist**. This novel role for human serum transferrin in the regulation of glucose metabolism provides a reasonable mechanism for the diabetogenic effect of GH, and has important implications for the etiology and progression of diabetes.

ACCESSION NUMBER: 1998125211 EMBASE  
TITLE: Insulin antagonism: A novel role for human serum transferrin.  
AUTHOR: Vargas L.; Kawada M.E.; Bazaes S.; Karplus P.A.; Faerman C.H.  
CORPORATE SOURCE: L. Vargas, Dept. of Cell and Molecular Biology, Pontifical Catholic Univ. of Chile, Casilla 114-D, Santiago, Chile  
SOURCE: Hormone and Metabolic Research, (1998) 30/3 (113-117).  
Refs: 34  
ISSN: 0018-5043 CODEN: HMMRA2  
COUNTRY: Germany  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 003 Endocrinology  
030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L7 ANSWER 28 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

TI The **insulin-antagonist** effect of the counterregulatory hormones.

AB The counterregulatory hormones glucagon, adrenaline, cortisol and growth hormone are released during hypoglycaemia, and under other stress conditions. These hormones have insulin-antagonistic effects both in the

liver and in the peripheral tissues. The insulin-antagonistic effects of glucagon and adrenaline are of rapid onset, whereas those of cortisol and growth hormone are only observed after a lag period of several hours. Glucagon is the most important hormone for acute glucose counterregulation. When the release of this hormone is deficient, as in patients with insulin-dependent diabetes, adrenaline becomes the most important hormone for glucose recovery during hypoglycaemia. Cortisol and growth hormone contribute to counterregulation during prolonged hypoglycaemia, but adrenaline is also of utmost importance in this condition. Adrenaline induces the early posthypoglycaemic insulin resistance, whereas cortisol and growth hormone are important for the insulin resistance that is observed later following hypoglycaemia. However, the importance of posthypoglycaemic insulin resistance for induction of posthypoglycaemic hyperglycaemia in clinical situations is limited. The pronounced insulin-antagonistic effect of growth hormone indicates that this hormone, in addition to its effect on the dawn phenomenon, could also play a key role in the regulation of other diurnal rhythms of glucose metabolism.

ACCESSION NUMBER: 91193036 EMBASE  
DOCUMENT NUMBER: 1991193036  
TITLE: The **insulin-antagonist** effect of the counterregulatory hormones.  
AUTHOR: Lager I.  
CORPORATE SOURCE: Department of Medicine II, Sahlgrenska Hospital, University of Goteborg, S-413 45 Goteborg, Sweden  
SOURCE: Journal of Internal Medicine, Supplement, (1991) 229/735 (41-47).  
ISSN: 0955-7873 CODEN: JIMSE3  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Conference Article  
FILE SEGMENT: 003 Endocrinology  
006 Internal Medicine  
030 Pharmacology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L7 ANSWER 29 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

TI Demonstration of heterogeneity of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing.

AB With isoelectric focusing, we examined heterogeneity of autoantibodies to insulin receptors in serums of two patients with insulin-resistant diabetes and one patient with **hypoglycemia**. Immunoglobulins were prepared by ammonium sulfate precipitation and ion-exchange chromatography with DEAE-Sepharose and subjected to isoelectric focusing for separation into 30 fractions. The fractions were tested for their ability to inhibit 125I-labeled insulin binding to human placental membranes, immunoprecipitate solubilized insulin receptor cross-linked with 125I-insulin, and mimic or inhibit the action of insulin in rat adipocytes. The results varied among the three patients. In the first patient, inhibition of 125I-insulin-binding activity (IBA) and insulin-receptor-precipitating activity (IPA) were distributed almost identically, but the distribution of insulinlike bioactivity (ILBA) was somewhat different. In the second patient, some fractions exhibited potent IBA without IPA, and these fractions inhibited the action of insulin in rat adipocytes. In the third patient, all of the isoelectric fractions showed IBA without IPA and were insulin antagonists. These observations indicate that some patients have antibodies with pure **insulin-antagonist** properties and provide further evidence that autoantibodies to insulin receptors are polyclonal and recognize different antigenic sites on insulin-receptor molecules. The findings also suggest that the ability of antibodies to elicit ILBA is linked to the ability to immunoprecipitate 125I-insulin-crosslinked and solubilized receptors,

whereas antibodies that only inhibit insulin binding behave as insulin antagonists.

ACCESSION NUMBER: 89250438 EMBASE  
DOCUMENT NUMBER: 1989250438  
TITLE: Demonstration of heterogeneity of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing.  
AUTHOR: Tsushima T.; Omori Y.; Murakami H.; Hirata Y.; Shizume K.  
CORPORATE SOURCE: Second Department of Medicine, Tokyo Women's Medical College, Tokyo 162, Japan  
SOURCE: Diabetes, (1989) 38/9 (1090-1096).  
ISSN: 0012-1797 CODEN: DIAEAB  
COUNTRY: United States  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 026 Immunology, Serology and Transplantation  
003 Endocrinology  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L7 ANSWER 30 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

TI Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.

AB Continuous, low dose, insulin infusion in conscious dogs produced moderate **hypoglycemia** but only a transient fall in glucose production that rose towards preinfusion levels 20 to 30 min before any detectable increase in plasma counterregulatory hormones. Addition of epinephrine or glucagon to the insulin infusion prevented the fall in glucose production throughout the experiment but only partially diminished the hypoglycemic response. When **hypoglycemia** was prevented by a variable glucose infusion, neither epinephrine nor glucagon was able to counteract the suppressive effect of insulin on glucose output. These findings suggest that a fall in blood glucose per se may reverse insulin-induced inhibition of glucose production independent of a rise in counterregulatory hormones and that the **insulin antagonist** effect of counterregulatory hormones is modulated, at least in part, by blood glucose concentration.

ACCESSION NUMBER: 79203514 EMBASE  
DOCUMENT NUMBER: 1979203514  
TITLE: Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.  
AUTHOR: Sacca L.; Cryer P.E.; Sherwin R.S.  
CORPORATE SOURCE: Dept. Int. Med., Yale Univ. Sch. Med., New Haven, Conn. 06510, United States  
SOURCE: Diabetes, (1979) 28/6 (533-536).  
CODEN: DIAEAB  
COUNTRY: United States  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 037 Drug Literature Index  
003 Endocrinology  
LANGUAGE: English

L7 ANSWER 31 OF 32 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

TI Hypoglycaemic effects of salivary duct ligation upon diabetes mellitus in mice.

AB The effect of bilateral ligation of the ducts of the submandibular gland or the parotid gland alone or of both glands upon blood sugar levels were investigated in adult male non diabetic Connought Swiss, non diabetic and streptozotocin induced diabetic C57BL/6J and mutant diabetic C57BL/KsJ db/db mice. The hypoglycaemic effect was only consistent and significant when both the parotid and submandibular ducts were simultaneously ligated bilaterally. This effect was most pronounced in mutant diabetic mice. The

mechanism of this effect is discussed with regard to the possible existence of an **insulin antagonist** produced in the submandibular gland.

ACCESSION NUMBER: 77072057 EMBASE  
DOCUMENT NUMBER: 1977072057  
TITLE: Hypoglycaemic effects of salivary duct ligation upon diabetes mellitus in mice.  
AUTHOR: Hoshino K.; Decker R.F.; Molnar F.; Kim Y.T.  
CORPORATE SOURCE: Cell. Biol. Res. Lab., Dept. Anat., Fac. Med. Dent., Univ. Manitoba, Winnipeg, Canada  
SOURCE: Archives of Oral Biology, (1976) 21/2 (105-111).  
CODEN: AOBIAR  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 003 Endocrinology  
002 Physiology  
LANGUAGE: English

L7 ANSWER 32 OF 32 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin.

AN 2000-430142 [37] WPIDS

AB US 6069193 A UPAB: 20000807

NOVELTY - Treating type II diabetes mellitus comprises administering transferrin to a mammal suffering from type II diabetes mellitus.

ACTIVITY - Antidiabetic. Intact rats were treated with alpha 2-glycoprotein (GP) alone or in association with a high, **hypoglycemia**-inducing dose of insulin. In all cases, 0.4 immunizing units (IU) insulin per 100 g body weight was used to induce **hypoglycemia**. Inhibition of severe insulin-induced **hypoglycemia** by alpha 2-GP occurred in five intact rats (n=5). Consistent with the high dose of insulin used, the insulin control developed severe **hypoglycemia** with one of the rats dying at 120 min with no detectable blood glucose. alpha 2-GP alone led to a rapid and broad **hypoglycemia**, and when given 10 min before insulin, it showed remarkable ability to antagonize the insulin-induced **hypoglycemia**.

MECHANISM OF ACTION - **Insulin antagonist**. The 80 %-pancreatectomized (80 %-P) rat model was used to assess the effect of alpha 2-GP on insulin levels showed that alpha 2-GP caused a rapid and profound hypoinsulinemia. Insulin levels were monitored in 80 %-P rats after treatment with 50 micro g alpha 2-GP or after 60 min of restrained stress. The resting insulin levels ranged from 8.5-11 micro U/ml, so that the maximal delta -insulinemia of -8.0 seen was dramatic. Results showed that alpha 2-GP did not only antagonize the effects of circulating insulin but also blocked the release of new insulin.

USE - Transferrin is useful for treating type II diabetes mellitus, for decreasing insulin production or serum concentration of insulin in mammals and mammalian cells, and for treating a mammal suffering from or susceptible to **hypoglycemia**.

ADVANTAGE - The new method effectively antagonizes insulin, and increases glycemic control to lessen adverse effects of diabetes.

Dwg.0/7

ACCESSION NUMBER: 2000-430142 [37] WPIDS

DOC. NO. NON-CPI: N2000-320910

DOC. NO. CPI: C2000-130642

TITLE: Treating type II diabetes mellitus or **hypoglycemia**, and decreasing insulin production or serum insulin level comprises administering transferrin.

DERWENT CLASS: B04 S03

INVENTOR(S): FAERMAN, C H; KARPLUS, P A; VARGAS, L A

PATENT ASSIGNEE(S): (CORR) CORNELL RES FOUND INC

COUNTRY COUNT: 1



PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 6069193	A	20000530	(200037)*		16

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 6069193	A Div ex	US 1996-585355	19960111
		US 1998-167853	19981007

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 6069193	A Div ex	US 5849293

PRIORITY APPLN. INFO: US 1996-585355 19960111; US  
1998-167853 19981007

=> d his

(FILE 'HOME' ENTERED AT 17:31:47 ON 09 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 17:33:04  
ON 09 SEP 2004

L1 47616 S HYPERGYLCEMIA OR HYPOGLYCEMIA  
L2 17 S L1 AND NON-PEPTIDYL COMPOUND  
L3 13598 S L1 AND TREATMENT  
L4 10 S L3 AND INSULIN AGONIST  
L5 135 S INSULIN ANTAGONIST  
L6 1 S L5 AND L4  
L7 32 S L5 AND L1

=> s l1 and insulin receptor  
L8 665 L1 AND INSULIN RECEPTOR

=> s l8 and binding  
L9 470 L8 AND BINDING

=> s l9 and l2  
L10 14 L9 AND L2

=> d l10 ti abs ibib tot

L10 ANSWER 1 OF 14 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any  
one of its **binding** proteins and not to a human IGF receptor.  
These IGF agonist compounds, which include peptides, are useful to  
increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:85155 USPATFULL

TITLE: Insulin-like growth factor agonist molecules

INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND

Lowman, Henry B., El Granada, CA, United States

Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6716586	B1	20040406
APPLICATION INFO.:	US 2000-724065		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5371		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules

AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:78964 USPATFULL

TITLE: Insulin-like growth factor agonist molecules

INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6713451	B1	20040330
APPLICATION INFO.:	US 2000-724062		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5379		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules

AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:41453 USPATFULL

TITLE: Insulin-like growth factor agonist molecules

INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND

PATENT ASSIGNEE(S): Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693079	B1	20040217
APPLICATION INFO.:	US 2000-724157		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5389		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 14 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor.  
These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2004:41452 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693078	B1	20040217
APPLICATION INFO.:	US 2000-724095		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	65 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5369		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 14 USPATFULL on STN  
TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor.  
These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:34008 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6689751	B1	20040210
APPLICATION INFO.:	US 2000-723912		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5377		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:21596 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Devonport, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6683053	B1	20040127
APPLICATION INFO.:	US 2000-723913		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Dreger, Esq., Ginger R., Heller Ehrman White & McAuliffe LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5367		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules

AB        Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:        2004:15030    USPATFULL  
TITLE:                    Insulin-like growth factor agonist molecules  
INVENTOR(S):             Clark, Ross G., Auckland, NEW ZEALAND  
                           Lowman, Henry B., El Granada, CA, United States  
                           Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S):      Genentech, Inc., South San Francisco, CA, United States  
                           (U.S. corporation)

	NUMBER	KIND	DATE
-----			
PATENT INFORMATION:	US 6680298	B1	20040120
APPLICATION INFO.:	US 2000-724114		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	44 Drawing Figure(s); 49 Drawing Page(s)		
LINE COUNT:	5376		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10    ANSWER 8 OF 14    USPATFULL on STN

TI        Insulin-like growth factor agonist molecules  
AB        Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:        2004:9592    USPATFULL  
TITLE:                    Insulin-like growth factor agonist molecules  
INVENTOR(S):             Clark, Ross G., Auckland, NEW ZEALAND  
                           Lowman, Henry B., El Granada, CA, United States  
                           Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S):      Genentech, Inc., South San Francisco, CA, United States  
                           (U.S. corporation)

	NUMBER	KIND	DATE
-----			
PATENT INFORMATION:	US 6677305	B1	20040113
APPLICATION INFO.:	US 2000-723873		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5359		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:296863 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6645775	B1	20031111
APPLICATION INFO.:	US 2000-723931		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	67 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5386		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which includes peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:279179 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6635619	B1	20031021
APPLICATION INFO.:	US 2000-724127		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		

LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller, Ehrman, White & McAuliffe, LLP  
NUMBER OF CLAIMS: 5  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 44 Drawing Figure(s); 49 Drawing Page(s)  
LINE COUNT: 5375  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:273418 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6632794	B1	20031014
APPLICATION INFO.:	US 2000-723547		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
LEGAL REPRESENTATIVE:	Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White & McAuliffe, LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	5360		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any one of its **binding** proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:246897 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C.A.F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6620789	B1	20030916
APPLICATION INFO.:	US 2000-723901		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar		

1998 Continuation-in-part of Ser. No. US 1997-825852,  
filed on 4 Apr 1997, now patented, Pat. No. US 6121416

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Romeo, David S.  
LEGAL REPRESENTATIVE: Hasak, Esq., Janet E., Heller Ehrman White & McAuliffe,  
LLP  
NUMBER OF CLAIMS: 9  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 66 Drawing Figure(s); 44 Drawing Page(s)  
LINE COUNT: 5398  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any  
one of its **binding** proteins and not to a human IGF receptor.  
These IGF agonist compounds, which include peptides, are useful to  
increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:222090 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, NEW ZEALAND  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 6608031	B1	20030819
APPLICATION INFO.:	US 2000-723890		20001128 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-52888, filed on 31 Mar 1998, now patented, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Romeo, David S.  
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Ginger R., Heller Ehrman White  
& McAuliffe, LLP  
NUMBER OF CLAIMS: 7  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 68 Drawing Figure(s); 44 Drawing Page(s)  
LINE COUNT: 5363  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 14 USPATFULL on STN

TI Insulin-like growth factor agonist molecules  
AB Compounds are provided that inhibit the interaction of an IGF with any  
one of its **binding** proteins and not to a human IGF receptor.  
These IGF agonist compounds, which include peptides, are useful to  
increase serum and tissue levels of active IGFs in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:97888 USPATFULL  
TITLE: Insulin-like growth factor agonist molecules  
INVENTOR(S): Clark, Ross G., Auckland, New Zealand  
Lowman, Henry B., El Granada, CA, United States  
Robinson, Iain C. A. F., St. Albans, United Kingdom  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)



	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251865	B1	20010626
APPLICATION INFO.:	US 1998-52888		19980331 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, now patented, Pat. No. US 6121416		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David		
LEGAL REPRESENTATIVE:	Hasak, Janet E.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	4925		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.